title: In vitro activity of 4'-iodo-4'-deoxydoxorubicin on human colo-rectal cancer as measured by a short-term antimetabolic assay.
abstract: A short-term antimetabolic assay based upon the inhibition of incorporation of nucleic acid precursors was used to compare the cytotoxicity of a new halogenated anthracycline, 4'-iodo-4'-deoxydoxorubicin (IDX), with that of its parent compound doxorubicin (DX) on human colo-rectal carcinoma specimens. IDX showed a marked dose-dependent effect, with frequencies of activity consistently greater than those of DX at all concentrations. The minimal dose required to induce a significant antimetabolic effect for IDX was 1/10 that for DX.
authors.affiliation: Oncologia Sperimentale C, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy.
authors.forename: R
authors.initials: R
authors.lastname: Villa
authors.forename: N
authors.initials: N
authors.lastname: Zaffaroni
authors.forename: F
authors.initials: F
authors.lastname: Giuliani
authors.forename: G
authors.initials: G
authors.lastname: Colella
authors.forename: O
authors.initials: O
authors.lastname: Sanfilippo
authors.forename: R
authors.initials: R
authors.lastname: Silvestrini
mesh_terms: D015179:Colorectal Neoplasms / Q000378:metabolism*; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D013936:Thymidine / Q000378:metabolism; D014407:Tumor Cells, Cultured / Q000187:drug effects / Q000378:metabolism; D014529:Uridine / Q000378:metabolism
chemical_list: C053044:4'-deoxy-4'-iododoxorubicin; D004317:Doxorubicin; D013936:Thymidine; D014529:Uridine